Together, these results suggest that decreased TRIM4 expression is linked to TAM resistance and poor prognostic outcomes for ER‐α positive breast cancer patients undergoing adjuvant TAM therapy, in line with our results from in vitro studies using TAM‐resistant breast cancer cell lines. This evidence concerns the gene ESR1 and breast carcinoma.